Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

03:10 EDT 30th April 2017 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 12,000+

Extremely Relevant

Research shows how protein component of Epstein-Barr virus promotes development of cancer

After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms.


Epstein-Barr virus and cancer: New tricks from an old dog

(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Approximately 98 percent of all adults are infected with the Epstein-Barr virus. In rare cases, an infection with this virus causes cancer. Scientists at the German Cancer Research Center (DKFZ), at the German Center for Infection Research (DZIF), and at the French Inserm have now discovered that a component of the Epstein-B...

T Cells Targeting Epstein-Barr Virus -- A New Treatment for MS?

This new approach -- based on the theory that the Epstein-Barr virus plays a causative role in MS -- has shown encouraging results in a preliminary study. Medscape Medical News


Epstein-Barr virus-positive follicular lymphoma

Cell Medica Raises £60M for Phase II T-Cell Product and Cell Immunotherapy Pipeline

Cell Medica raised $60 million in a Series C round of financing to support development of its cell-based immunotherapy platforms and pipeline, including lead mid-stage oncology candidate, baltaleucel-T (CMD-003). The autologous T-cell therapy is being evaluated in the Phase II CITADEL study and the CIVIC trial, as a treatment for advanced lymphomas associated with Epstein Barr virus (EBV). Par...

Causing Cancer at (a Chromosome's) Arm's Length

Yes, the Epstein-Barr Virus is carcinogenic, but in an unexpected way. Read more...

Series C round brings £60mm to Cell Medica

Cell Medica Ltd. (cellular immunotherapy) raised £60mm ($73.2mm) through its Series C round from returning investors Touchstone Innovations (formerly Imperial Innovations), funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management. Proceeds will help the company continue work on its three T-cell immunotherapy platforms (Streptamer, OneTouch, and T-cellerator), and wi...

Epstein-Barr Virus in Pediatric Patients With Acute B-ALL

What role might regulatory T cells and EBV infection play in the pathogenesis of childhood acute B lymphoblastic leukemia? Journal of Clinical Pathology

Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Separate Indicati

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the designs of two Phase 3 trials for ATA 129 intended to supp...

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated P

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that pursuant to parallel scientific advice from the European Medicines Agency’s (EMA’s) Scientific...

Aethlon Medical begins sepsis-related virus study

Aethlon Medical has started Sepsis-related virus study, focusing on cytomegalovirus, epstein-barr and herpes simplex viruses.

Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL Outcomes

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.

Highlighting Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL Outcomes

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.

Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes

Monocytes/macrophages are activated in several autoimmune diseases, including systemic sclerosis (scleroderma; SSc), with increased expression of interferon (IFN)-regulatory genes and inflammatory cytokines, s...

More evidence that Zika mRNA vaccines can stop viral replication in mice

(Cell Press) Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune system to recognize a future infection. The research, published Feb. 17 in Cell, follows a Feb. 2 Letter in Nature (doi:10.1038/nature21428) that showed similar p...

Modifying a live virus in a vaccine to be just strong enough

By genetically tweaking the constituent live virus, scientists have created a vaccine against influenza in which the virus is capable of activating the immune system but cannot replicate in healthy cells -- an approach that may become more widely used for generating live virus vaccines adapted to other viruses.

Zika Virus Infection and Guillain-Barré Syndrome

Guillain-Barré syndrome is a defined complication of Zika virus infection and presents in a typical manner, similar to other post-viral GBS syndromes.

Powerful Zika Vaccine Protects Mice and Monkeys from the Virus

(New Scientist) – A new vaccine against Zika virus gives mice and monkeys immunity in tests. The vaccine is based on the inactivated virus, and just one low dose is needed. “The critical difference between ours and everybody else’s is … Read More

New, More Effective Strategy for Producing Flu Vaccines

The technology is an influenza B vaccine virus &"backbone&" that would allow producers to grow vaccine viruses at high yield in mammalian cell culture rather than in eggs

Engineered Flu Virus a Replicative Dud, but Stays Live

By genetically tweaking the constituent live virus, scientists have created a vaccine against influenza in which the virus is capable of activating the immune system but cannot replicate in healthy cells - an approach that may become more widely used for generating live virus vaccines adapted to other viruses. The vaccine proved effective in mice, guinea pigs and ferrets. A major challenge in deve...

Scientists find gene variants causing NK cell deficiency, solving 12 year-long mystery for a family

An international team of scientists has solved a medical mystery that has affected a family for more than 40 years. The condition made most of the children in the family susceptible to severe viral infections, Epstein-Barr virus in particular. Two of the four siblings died due to the infections, one was unaffected by the condition and one has survived repeated infections. Discovering the cause of ...

Researchers develop first chikungunya vaccine from virus that does not affect people

Researchers from The University of Texas Medical Branch at Galveston have developed the first vaccine for chikungunya fever made from an insect-specific virus that doesn't have any effect on people, making the vaccine safe and effective. The newly developed vaccine quickly produces a strong immune defense and completely protects mice and nonhuman primates from disease when exposed to the chikungun...

Five HIV patients are ‘virus and drug free’ and no longer infectious after two doses of new vaccine – The Sun

The SunFive HIV patients are 'virus and drug free' and no longer infectious after two doses of new vaccineThe SunFIVE people with HIV are 'virus free' after receiving two doses of an experimental new vaccine, scientists have revealed. The participants no longer infectious and don't need to take daily medication to keep the virus at bay. Five people with HIV are ...How Uganda got results in its fig...

NIH respiratory syncytial virus vaccine enters clinical testing

A phase I clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the NIH Clinical Center in Bethesda, Maryland. The trial will also assess the vaccine’s ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at […] The post NIH respiratory sy...


Quick Search
Advertisement
 

News Quicklinks